Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.

• Tác giả: John Bartlett, Bent Ejlertsen, Maj-Britt Jensen, Anne-Vibeke Lænkholm, Torsten O Nielsen, Lois Shepherd
• Ngôn ngữ: eng
• Ký hiệu phân loại: 368.14 *War risk insurance
• Thông tin xuất bản: United States : NPJ breast cancer , 2025
• Bộ sưu tập: NCBI
• ID: 686074

Tóm tắt

 NCIC-CTG MA.5 and DBCG 89D are symmetrically designed randomized trials comparing adjuvant cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in high-risk breast cancer patients. In a joint analysis we evaluate the predictive value in terms of anthracycline benefit of molecular subtyping by PAM50. A statistically significant interaction (P = 0.008) between continuous Risk of Recurrence (ROR) score and treatment regimen is evident, translating into a clear distinct treatment effect according to ROR score category with HR 0.51 for ROR score ≥ 72 and HR 1.10 for ROR score <
  52 (P